至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis

Cell Immunol. 2020; 
João A Oliveira-da-Silva, Amanda S Machado, Fernanda F Ramos, Grasiele S V Tavares, Daniela P Lage, Débora V C Mendonça, Isabela A G Pereira, Thaís T O Santos, Vívian T Martins, Lívia M Carvalho, Camila S Freitas, Fernanda Ludolf, Thiago A R Reis, Raquel S Bandeira, Alessandra M Silva, Lourena E Costa, Jamil S Oliveira, Mariana C Duarte, Bruno M Roatt, Antônio L Teixeira, Eduardo A F Coelho
Products/Services Used Details Operation
Recombinant Antibody Expression … 2. Materials and methods. 2.1. Production of the immunogens. To obtain the recombinant protein, DNA codifying LiHyJ (XP_001462647.1) sequence was commercially cloned from L. infantum kDNA into the pET-28a(+)-TEV vector (Genscript®, USA) … Get A Quote

摘要

Most studies evaluating vaccine candidates against visceral leishmaniasis (VL) have used parasite promastigote-expressed antigens; however, Leishmania proteins expressed in the amastigote forms should be considered, since few hours after infection this stage comes into contact with the host immune system and is responsible for the development of the disease. In this context, in the present study, a Leishmania amastigote-specific hypothetical protein, called LiHyJ, was evaluated as a recombinant protein plus saponin as an adjuvant or DNA vaccine to protect against VL. The vaccine effect was evaluated by means of the evaluation of immunological and parasitological analyses performed in BALB/c mice against Leishma... More

关键词

Amastigote antigens, Hypothetical proteins, Immune response, Vaccine, Visceral leishmaniasis